GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (STU:0IT) » Definitions » Beta

Satellos Bioscience (STU:0IT) Beta : 0.65 (As of Dec. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-12-12), Satellos Bioscience's Beta is 0.65.


Satellos Bioscience Beta Historical Data

The historical data trend for Satellos Bioscience's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience Beta Chart

Satellos Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Beta
- - - -

Satellos Bioscience Quarterly Data
Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 1.09

Competitive Comparison of Satellos Bioscience's Beta

For the Biotechnology subindustry, Satellos Bioscience's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Satellos Bioscience's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Satellos Bioscience's Beta distribution charts can be found below:

* The bar in red indicates where Satellos Bioscience's Beta falls into.



Satellos Bioscience Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Satellos Bioscience  (STU:0IT) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Satellos Bioscience Beta Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Satellos Bioscience Business Description

Traded in Other Exchanges
Address
200 Bay Street, Suite 2800, Royal Bank Plaza, South Tower, Toronto, ON, CAN, M5J 2J1
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience Headlines

No Headlines